Claudin 18.2 Expression in Cholangiocarcinoma: Clinicopathological Heterogeneity, Prognostic Significance, and Impact of Positivity Thresholds
Background/Objectives: Claudin 18.2 (CLDN18.2) has emerged as a clinically actionable therapeutic target in gastrointestinal malignancies; however, its expression profile and prognostic significance in cholangiocarcinoma (CCA) remain incompletely characterized. This study investigated CLDN18.2 expression in CCA and eva...